Article
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Blood - 2 May 2013
Hochhaus Andreas, Saglio Giuseppe, Larson Richard A, Kim Dong-Wook, Etienne Gabriel, Rosti Gianantonio, De Souza Carmino, Kurokawa Mineo, Kalaycio Matt E, Hoenekopp Albert, Fan Xiaolin, Shou Yaping, Kantarjian Hagop M, Hughes Timothy P
Abstract excerpt
In patients with chronic myeloid leukemia, BCR-ABL mutations contribute to resistance to tyrosine kinase inhibitor therapy. We examined the occurrence of treatment-emergent mutations and their impact on response in patients from the ENESTnd phase 3 trial. At the 3-year data cutoff, mutations were detected in approximately twice as many patients (21) on imatinib 400 mg once daily as on nilotinib (11 patients each...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.